19
Mar
By Marie-Laure Combet and Lena Boucon | Orrick
A decade ago, the European Commission conducted a thorough sectoral inquiry into the European pharmaceutical sector that identified antitrust shortcomings impeding access to more affordable and innovative medicines and treatments. Concluding this inquiry by setting priority actions for the years to come, former Competition Commissioner Kroes called for “… more competition and less red tape …” (sic).
Since this statement, there has been intense enforcement activity in the sector not only by the European Commission itself,...